Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 322

1.

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP.

Blood. 2009 Jun 18;113(25):6403-10. doi: 10.1182/blood-2009-02-205690. Epub 2009 Apr 16.

PMID:
19372255
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mutation in TET2 in myeloid cancers.

Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA.

N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069.

PMID:
19474426
[PubMed - indexed for MEDLINE]
Free Article
3.

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shooter C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, Germing U, Mufti GJ.

Blood. 2010 Nov 11;116(19):3923-32. doi: 10.1182/blood-2010-03-274704. Epub 2010 Aug 6.

PMID:
20693430
[PubMed - indexed for MEDLINE]
Free Article
4.

TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.

Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S, Kern W, Haferlach T, Haferlach C.

Br J Haematol. 2012 Jan;156(1):67-75. doi: 10.1111/j.1365-2141.2011.08911.x. Epub 2011 Oct 24.

PMID:
22017486
[PubMed - indexed for MEDLINE]
5.

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, Rumi E, Pietra D, Malcovati L, Elena C, Doubek M, Steurer M, Tosic N, Pavlovic S, Guglielmelli P, Pieri L, Vannucchi AM, Gisslinger H, Cazzola M, Kralovics R.

Am J Hematol. 2012 Mar;87(3):245-50. doi: 10.1002/ajh.22257. Epub 2011 Dec 21.

PMID:
22190018
[PubMed - indexed for MEDLINE]
6.

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.

Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.

PMID:
19420352
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.

Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP.

Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. doi: 10.1002/gcc.20748.

PMID:
20095039
[PubMed - indexed for MEDLINE]
9.

Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.

Klaus M, Psaraki A, Mastrodemou S, Pyrovolaki K, Mavroudi I, Kalpadakis C, Papadaki HA.

Leuk Res. 2011 Mar;35(3):413-5. doi: 10.1016/j.leukres.2010.10.023. Epub 2010 Nov 18.

PMID:
21087791
[PubMed - indexed for MEDLINE]
10.

Acquired mutations in TET2 are common in myelodysplastic syndromes.

Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH.

Nat Genet. 2009 Jul;41(7):838-42. doi: 10.1038/ng.391. Epub 2009 May 31.

PMID:
19483684
[PubMed - indexed for MEDLINE]
11.

High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.

Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL, Dastugue N, Macintyre E, Denis C, Bauters F, Kerckaert JP, Cosson A, Fenaux P.

Blood. 2000 Oct 15;96(8):2862-9.

PMID:
11023523
[PubMed - indexed for MEDLINE]
Free Article
12.

Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.

Larsson N, Lilljebjörn H, Lassen C, Johansson B, Fioretos T.

Eur J Haematol. 2012 Feb;88(2):136-43. doi: 10.1111/j.1600-0609.2011.01710.x. Epub 2011 Nov 17.

PMID:
21933280
[PubMed - indexed for MEDLINE]
13.

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.

Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A.

Nature. 2010 Dec 9;468(7325):839-43. doi: 10.1038/nature09586.

PMID:
21057493
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.

Bacher U, Haferlach C, Schnittger S, Kohlmann A, Kern W, Haferlach T.

Ann Hematol. 2010 Jul;89(7):643-52. doi: 10.1007/s00277-010-0920-6. Epub 2010 Mar 2. Review.

PMID:
20195608
[PubMed - indexed for MEDLINE]
15.

Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.

Nguyen-Khac F, Lesty C, Eclache V, Couronné L, Kosmider O, Andrieux J, Collonge-Rame MA, Penther D, Lafage M, Bilhou-Nabera C, Chapiro E, Mozziconacci MJ, Mugneret F, Gachard N, Nadal N, Lippert E, Struski S, Dastugue N, Cabrol C, Bernard OA; Groupe Francophone de Cytogénétique Hématologique.

Genes Chromosomes Cancer. 2010 Oct;49(10):919-27. doi: 10.1002/gcc.20802.

PMID:
20629097
[PubMed - indexed for MEDLINE]
16.

RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.

Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, Lambertenghi Deliliers G, Beran M, Onida F.

Clin Cancer Res. 2010 Apr 15;16(8):2246-56. doi: 10.1158/1078-0432.CCR-09-2112. Epub 2010 Apr 6.

PMID:
20371679
[PubMed - indexed for MEDLINE]
Free Article
17.

Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.

Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C, Delannoy A, Devidas A, Gardembas-Pain M, Isnard F, Plumelle Y, Bernard O, Vainchenker W, Najman A, Bellanné-Chantelot C; French Group of Familial Myeloproliferative Disorders.

Blood. 2009 Aug 20;114(8):1628-32. doi: 10.1182/blood-2009-01-197525. Epub 2009 Jun 29.

PMID:
19564637
[PubMed - indexed for MEDLINE]
Free Article
18.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, Dicker F, Schnittger S, Dugas M, Kern W, Haferlach C, Haferlach T.

J Clin Oncol. 2010 Aug 20;28(24):3858-65. doi: 10.1200/JCO.2009.27.1361. Epub 2010 Jul 19.

PMID:
20644105
[PubMed - indexed for MEDLINE]
19.

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B.

Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.

PMID:
21904853
[PubMed - indexed for MEDLINE]
20.

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, Strupp C, Gattermann N, Germing U, Mufti GJ.

J Clin Oncol. 2009 Aug 20;27(24):4002-6. doi: 10.1200/JCO.2009.22.6985. Epub 2009 Jun 15.

PMID:
19528370
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk